APA (7th ed.) Citation

Powell, M., Zub, O., Gilbert, L., Koliadi, A., Willmott, L., Black, D., . . . Nøttrup, T. (2026). Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology, 208, S65. https://doi.org/10.1016/j.ygyno.2026.01.779

Chicago Style (17th ed.) Citation

Powell, Matthew, et al. "Four-year Survival Outcomes with Dostarlimab Plus Chemotherapy in DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Gynecologic Oncology 208 (2026): S65. https://doi.org/10.1016/j.ygyno.2026.01.779.

MLA (9th ed.) Citation

Powell, Matthew, et al. "Four-year Survival Outcomes with Dostarlimab Plus Chemotherapy in DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial." Gynecologic Oncology, vol. 208, 2026, p. S65, https://doi.org/10.1016/j.ygyno.2026.01.779.